Introduction
There are recent reports of a beneficial effect of phototherapy using ultraviolet (UV) radiation in the management of lupus erythematosus (LE)1-3. McGrath and his colleagues at Louisiana State University have found exposure to the longer wavelengths of UVA (320-400 nm) radiation, so-called UVA-1 (340-400 nm), can relieve the systemic symptoms of LE, clear cutaneous lesions in some patients and improve the serological profile. These findings are quite contrary to the conventional wisdom of UV radiation being harmful to most patients with LE and a review of this information is perhaps timely.
At first blush the idea of deliberately exposing a photosensitive patient to UV radiation appears foolhardy with clear potential for causing harm. However, dennatologists have been doing this for years and the first report was published more than 40 years ago~, a case of solar urticaria treated with an artificial source of UV radiation. More recently, studies have demonstrated PUVA {l'sa~ral~nlLTVA radiation) therapy and UVB (280-320 nm) phototherapy to be safe and effective in polymorphous light eruption 5-7 chronic actinic dennatitis8 and solar urticaria9. The mechanisms by which UV radiation suppresses these conditions is unknown. However, McGrath's observations in LE go further than suppression of photosensitive skin lesions because he is reporting relief of systemic symptoms and signs of disease and this presupposes a systemic effect of UV radiation compared with a purely local cutaneous effect at the site of exposure. This is also not surprising since systemic effects of UV radiation, in particular suppression of various immune responses, have been observed in mice0 and humans 11. A large number of studies from many centers have collectively demonstrated that UV radiation can be a very potent modulator of immune function. these thoughts in mind, the concept of using phototherapy for treatment of LE becomes more within the realm of possibility.
Photosensitivity and lupus
There are three levels of ph~tc~sensitivity in patients with LE. First, there are patients who develop cutaneous lesions as a direct result of exposure to sunlight and this is a particular feature of subacute cutaneous lupus crythematosus (SCLE) but is also seen in discoid and systemic lupus.
The action spectrum for these lesions involves both UVA and UVB radiation 12. The idea of dividing the UVA waveband into UVA-and UVA-2 (32C7-~~.~nm~, because of possible differences in their biologic effects, has only arisen in the past few years and it is not known whether patients with LE are sensitive to UV-1. A second level of photosensitivity in LE is seen in patients with cutaneous disease without a history of photosensitivity, in that the skin lesions tend to be more numerous on exposed areas and presumably sunlight plays some role in their production; the action spectrum for this effect is unknown. Finally, some patients have exacerbation of systemic disease following exposure to sunlight, although this is probably a rare phenomenon.
Animal studies Mouse models of lupus have been exposed to various wavebands of radiation. Chronic exposure of (NZB X NZW) F1 mice to UVC (essentially 254nm)) radiation'3 or UVB 14 radiation did not affect disease progression or mortality. A short-term (4 weeks) exposure to UVBIUV A radiation did greatly reduce survival of BxSB mice and this effect was eliminated by filtering the UVB radiation from the sources. In contrast, chronic exposure of NZB/W mice to UVA radiation enhanced survival and irradiated animals had smaller spleens, better mitogen responses and lower levels of anti-dsDNA antibodies compared with nonirradiated animals&dquo;. In a follow-up study, exposure to fluorescent cool-white bulbs 12h each day had similar effects on these disease parameters~~; these bulbs emit a small amount of UVA radiation. The interpretation of these studies is complicated by the use of different mouse strains, broadband radiation sources often without filters and variations in radiation protocols. However, the studies suggest that UVB radiation may enhance progression of disease and UVA may suppress the disease in mice. A parallel observation in another mouse model is that exposure to UVB radiation produces systemic suppression of contact hypersensitivity through generation of haptenspecific T, cells while exposure to filtered UVA radiation produces some enhancement of this immune response is
Studies in humans
Two studies have been completed and one study is ongoing.
In the first study', 15 patients with systemic LE were treated by exposure 5 days a week for 3 weeks to radiation from unfiltered Philips TL10R bulbs. These lamps emit mainly UVA-1 radiation but also small amounts of UVA-2 and UVB radiation. Various parameters were monitored and fatigue, joint pain, morning stiffness, fever, malaise, physician and patient assessment of disease activity decreased significantly (mean score improving 32%) while headache and serositis were not significantly improved. The mean score in two of the 15 patients did not improve. Half of the patients had anti-SSA antibodies and they had much greater improvement than SSA-negative patients. Two of three patients with cutaneous lesions had improvement of their rash. The results of this open and brief study appear encouraging in so far as most patients had improvement and no adverse effects were noted.
In the second study~ 10 patients with systemic LE were exposed on a similar schedule to radiation from Philips TL10R bulbs but wavelengths <340nm were filtered out using a plastic filter. The rationale for this change was that unfiltered bulbs can reduce the number of circulating T and B cellsl,19 but filtered bulbs do not have this effect. The results were similar with an overall improvement of the clinical score by about 40% after 3 weeks of treatment. Four patients continued long-term treatment and after 8 months of treatment two to three times each week these patients had 70% improvement in disease activity. One patient with SCLE had marked improvement of the cutaneous lesions and conversion from an anti-SSA positive to anti-SSA negative status. Overall there appeared to be improvement in serology, particularly in patients who were anti-SSA positive.
Finally, a controlled cross-over study in 25 patients with systemic LE found visible light (>430nm) to be without benefit while UVA-1 produced beneficial effects similar to those seen in the two open studies. This study is being continued to investigate the long-term effects of UVA-1 treatment.
Potential mechanisms
A detailed discussion of the possible mechanisms of a therapeutic effect of UVB-1 I in LE is probably too speculative and premature at this stage of our knowledge. However, there is one important and basic question. With our present knowledge, is it surprising that UVB and perhaps the shorter wavelengths of UVA radiation are harmful in patients with LE while UVA-I is beneficial? The answer is probably no, based on considerations at a molecular, tissue and organ level.
First, the photochemistry initiated by absorption of UVB and UVA photons appears to be quite different. For example, damage to DNA by UVB photons is caused by direct absorption of photons resulting in formation of pyrimidine dimers and other photoproducts. In contrast, UVA radiation produces damage to DNA by an indirect mechanism that is oxygen dependent and involves generation of reactive oxygen species which interact with DNA; the transition zone for these differences in photochemistry appears to be in the 320-350 nm waveband 21
A second consideration is the optical properties of the skin in respect of UVB and UVA radiation. UVB is almost wholly absorbed in the epidermis and only a small percentage is transmitted to the dermis. Again in contrast, most UVA-1 radiation is transmitted to the dermis. Thus, the sites of photochemistry initiated by these two wavebands are quite different and this may be important. For example, OVA-is more likely to influence the function of circulating lymphocytes, monocytes and other cells in the dermis while UVB radiation affects the function of Langerhans cells and keratinocytes in the epidermis. Finally, we know that UVB radiation is immunosuppressive in a selective manner and particularly influences delayed hypersensitivity responses. The scant knowledge we have suggests that UVA radiation does not have this effect.
Conclusion
These studies reporting a beneficial effect of LTVA-1 radiation in LE must be regarded as preliminary. However, the observations are very interesting. Exposure to UVA radiation does delay onset of disease in a mouse model of lupus but the obvious limitation of this observation is the question of the relevance of the model to human LE. The studies in humans have been small, of short duration and open with soft endpoints for assessment of improvement.
More studies are required in other centers to confirm the results, preferably utilizing crisper endpoints such as clearance of a rash on an exposed half of the body and not on a non-exposed other half of the body.
